Copanlisib

Copanlisib
Clinical data
Trade namesAliqopa
Other namesBAY 80-6946
AHFS/Drugs.comMonograph
MedlinePlusa617044
License data
Routes of
administration
Intravenous
Drug classPI3-Kinase inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding84.2%
MetabolismCYP3A4/5 (≈90%), CYP1A1 (≈10%)
Elimination half-life39.1 hours (range: 14.6 to 82.4)
ExcretionFeces (64%), Urine (22%); 14% were not recovered
Identifiers
  • 2-Amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H28N8O4
Molar mass480.529 g·mol−1
3D model (JSmol)
  • COC1=C(C=CC2=C1N=C(N3C2=NCC3)NC(=O)C4=CN=C(N=C4)N)OCCCN5CCOCC5
  • InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)
  • Key:PZBCKZWLPGJMAO-UHFFFAOYSA-N

Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.

In November 2023, Bayer announced that it was withdrawing copanlisib from the US market.